Increasing spend and improving access to healthcare despite slowing US growth is expected to aid domestic pharma industry, an Icra report said
7-9% – Growth in pharma sector seen during FY18-FY21
15.4% – Aggregate revenues of 21 firms in Q1 of this fiscal
27.2% – Aggregate domestic growth in Q1
8.6% – Aggregate R&D spends by domestic companies in the first quarter
8.8% – R&D spends during FY18
19.7% – Aggregate Ebidtda margins in Q1